84877-46-3

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 340-04-5 1-phenyl-2,2,2-trifluoromethylethanol 
• 434-45-7 2,2,2-Trifluoroacetophenone 
• 421-83-0 trifluoromethane sulfonyl chloride 

Downstream Products

• 84877-50-9 Trifluoro-acetic acid 2,2,2-trifluoro-1-phenyl-ethyl ester 
• 56893-91-5 2,2,2-trifluoro-1-phenylethane-1,1-diol 
• 340-04-5 1-phenyl-2,2,2-trifluoromethylethanol 
• 434-45-7 2,2,2-Trifluoroacetophenone 
• 849093-83-0 2(R)-3-cyclopropylmethylsulfanyl-2-(2,2,2-trifluoro-1(RS)-phenyl-ethylamino)propan-1-ol 
• 849093-92-1 2(R)-3-cyclopropylmethylsulfanyl-2-(2,2,2-trifluoro-1(R)-phenyl-ethylamino)propan-1-ol 
• 849093-91-0 2(R)-3-cyclopropylmethylsulfanyl-2-(2,2,2-trifluoro-1(S)-phenyl-ethylamino)propan-1-ol 
• 84194-69-4 (±)-2,2,2-trifluoro-1-phenylethyl acetate 
• 65432-43-1 2,2,2-trifluoro 1-phenyl-1-ethoxy-ethane 
• 880762-37-8 2(R)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino]-3-tritylsulfanyl-propionic acid 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

The present disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of the YAP:TEAD protein:protein interaction. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various YAP:TEAD-mediated disorders, including cancer.

AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Solvolysis of 1-Aryl-2,2,2-trifluoroethyl Sulfonates. Kinetic and Stereochemical Effects in the Generation of Highly Electron-Deficient Carbocations

Solvolysis rates of sulfonates XC6H4CH(O3SR)CF3 (R = p-Tol or CF3) correlate with ?+(X) with values of ρ+ between -6.7 and -11.9 depending upon solvent.For the tosylates the rates depend on the solvent parameter YOTs with